FIGHT against FGF/FGFR alterations: what are the next steps?

被引：4

作者：

Bayle, A. ^{[1
]}

Martin-Romano, P. ^{[1
]}

Loriot, Y. ^{[1
]}

机构：

[1] Gustave Roussy Univ Paris Saclay, Drug Dev Dept DITEP, Villejuif, France

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 05期

关键词：

METASTATIC CHOLANGIOCARCINOMA; OPEN-LABEL; MULTICENTER; ERDAFITINIB; BGJ398;

D O I：

10.1016/j.annonc.2022.03.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：460 / 462

页数：3

共 14 条

[1]

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study [J].

Abou-Alfa, Ghassan K. ;

Sahai, Vaibhav ;

Hollebecque, Antoine ;

Vaccaro, Gina ;

Melisi, Davide ;

Al-Rajabi, Raed ;

Paulson, Andrew S. ;

Borad, Mitesh J. ;

Gallinson, David ;

Murphy, Adrian G. ;

Oh, Do-Youn ;

Dotan, Efrat ;

Catenacci, Daniel, V ;

Van Cutsem, Eric ;

Ji, Tao ;

Lihou, Christine F. ;

Zhen, Huiling ;

Feliz, Luis ;

Vogel, Arndt .

LANCET ONCOLOGY, 2020, 21 (05) :671-684

[2]

Chen YY, 2018, ANN ONCOL, V29, P209

[3]

Mechanisms of acquired resistance to FGFR inhibitors in molecularly-selected solid tumors: A prospective cohort from the MATCH-R study [J].

Facchinetti, Francesco ;

Bahleda, Rastislav ;

Hollebecque, Antoine ;

Loriot, Yohann ;

Recondo, Gonzalo ;

Bigot, Ludovic ;

Olaussen, Ken A. ;

Vassal, Gilles ;

Michiels, Stefan ;

Frias, Rosa L. ;

Galissant, Justine ;

Sourisseau, Tony ;

Nicotra, Claudio ;

Ngo-Camus, Maud ;

Mahjoubi, Linda ;

Lacroix, Ludovic ;

Rouleau, Etienne ;

Richon, Catherine ;

Abou-Lovergne, Aurelie ;

Deas, Olivier ;

Auger, Nathalie ;

De Baere, Thierry ;

Deschamps, Frederic ;

Solary, Eric ;

Scoazec, Jean-Yves ;

Angevin, Eric ;

Eggermont, Alexander ;

Andre, Fabrice ;

Besse, Benjamin ;

Thiery, Jean-Paul ;

Soria, Jean-Charles ;

Massard, Christophe ;

Friboulet, Luc .

CANCER RESEARCH, 2019, 79 (13)

[4]

Javle M, 2021, LANCET GASTROENTEROL, V6, P803, DOI [10.1016/S2468-1253(21)00196, 10.1016/S2468-1253(21)00196-5]

[5]

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma [J].

Javle, Milind ;

Lowery, Maeve ;

Shroff, Rachna T. ;

Weiss, Karl Heinz ;

Springfeld, Christoph ;

Borad, Mitesh J. ;

Ramanathan, Ramesh K. ;

Goyal, Lipika ;

Sadeghi, Saeed ;

Macarulla, Teresa ;

El-Khoueiry, Anthony ;

Kelley, Robin Kate ;

Borbath, Ivan ;

Choo, Su Pin ;

Oh, Do-Youn ;

Philip, Philip A. ;

Chen, Li-Tzong ;

Reungwetwattana, Thanyanan ;

Van Cutsem, Eric ;

Yeh, Kun-Huei ;

Ciombor, Kristen ;

Finn, Richard S. ;

Patel, Anuradha ;

Sen, Suman ;

Porter, Dale ;

Isaacs, Randi ;

Zhu, Andrew X. ;

Abou-Alfa, Ghassan K. ;

Bekaii-Saab, Tanios .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (03) :276-+

[6]

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma [J].

Loriot, Y. ;

Necchi, A. ;

Park, S. H. ;

Garcia-Donas, J. ;

Huddart, R. ;

Burgess, E. ;

Fleming, M. ;

Rezazadeh, A. ;

Mellado, B. ;

Varlamov, S. ;

Joshi, M. ;

Duran, I. ;

Tagawa, S. T. ;

Zakharia, Y. ;

Zhong, B. ;

Stuyckens, K. ;

Santiago-Walker, A. ;

De Porre, P. ;

O'Hagan, A. ;

Avadhani, A. ;

Siefker-Radtke, A. O. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04) :338-348

[7]

Necchi A, 2018, ANN ONCOL, V29

[8]

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations [J].

Pal, Sumanta K. ;

Rosenberg, Jonathan E. ;

Hoffman-Censits, Jean H. ;

Berger, Raanan ;

Quinn, David I. ;

Galsky, Matthew D. ;

Wolf, Juergen ;

Dittrich, Christian ;

Keam, Bhumsuk ;

Delord, Jean-Pierre ;

Schellens, Jan H. M. ;

Gravis, Gwenaelle ;

Medioni, Jacques ;

Maroto, Pablo ;

Sriuranpong, Virote ;

Charoentum, Chaiyut ;

Burris, Howard A. ;

Grunwald, Viktor ;

Petrylak, Daniel ;

Vaishampayan, Ulka ;

Gez, Eliahu ;

De Giorgi, Ugo ;

Lee, Jae-Lyun ;

Voortman, Jens ;

Gupta, Sumati ;

Sharma, Sunil ;

Mortazavi, Amir ;

Vaughn, David J. ;

Isaacs, Randi ;

Parker, Katie ;

Chen, Xueying ;

Yu, Kun ;

Porter, Dale ;

Porta, Diana Graus ;

Bajorin, Dean F. .

CANCER DISCOVERY, 2018, 8 (07) :812-821

[9]

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study [J].

Schuler, Martin ;

Cho, Byoung Chuf ;

Sayehli, Cyrus Michael ;

Navarro, Alejandro ;

Soo, Ross A. ;

Richly, Heike ;

Cassier, Philippe Alexandre ;

Tai, David ;

Penel, Nicolas ;

Nagoya, Lucia ;

Park, Se Hoon ;

Schostak, Martin ;

Gajate, Pablo ;

Cathomas, Richard ;

Rajagopalan, Prabhu ;

Grevel, Joachim ;

Bender, Sebastian ;

Boix, Oliver ;

Nogai, Hendrik ;

Ocker, Matthias ;

Eflinghaus, Peter ;

Joerger, Markus .

LANCET ONCOLOGY, 2019, 20 (10) :1454-1466

[10]

Analysis of circulating tumor DNA (ctDNA) from the phase II BLC2001 trial of erdafitinib in locally advanced or metastatic urothelial carcinoma (mUC) to identify markers of intrinsic resistance to fibroblast growth factor receptor (FGFR)-targeted therapy [J].

Siefker-Radtke, A. O. ;

Loriot, Y. ;

Necchi, A. ;

Huddart, R. A. ;

Burgess, E. F. ;

Rezazadeh, A. ;

O'Hagan, A. ;

De Porre, P. ;

Avadhani, A. ;

Monga, M. ;

Cherkas, Y. ;

Moy, C. H. ;

Santiago-Walker, A. .

ANNALS OF ONCOLOGY, 2020, 31 :S584-S584

← 1 2 →